JP2019502741A - がんを処置するための方法 - Google Patents

がんを処置するための方法 Download PDF

Info

Publication number
JP2019502741A
JP2019502741A JP2018538604A JP2018538604A JP2019502741A JP 2019502741 A JP2019502741 A JP 2019502741A JP 2018538604 A JP2018538604 A JP 2018538604A JP 2018538604 A JP2018538604 A JP 2018538604A JP 2019502741 A JP2019502741 A JP 2019502741A
Authority
JP
Japan
Prior art keywords
patient
cancer
composition
immune checkpoint
checkpoint inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018538604A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019502741A5 (https=
Inventor
ロバート ディー アルバイト
ロバート ディー アルバイト
ポーラ マリー ラガン
ポーラ マリー ラガン
Original Assignee
エックス４ ファーマシューティカルズ， インコーポレイテッド
エックス４ ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エックス４ ファーマシューティカルズ， インコーポレイテッド, エックス４ ファーマシューティカルズ， インコーポレイテッド filed Critical エックス４ ファーマシューティカルズ， インコーポレイテッド
Publication of JP2019502741A publication Critical patent/JP2019502741A/ja
Publication of JP2019502741A5 publication Critical patent/JP2019502741A5/ja
Priority to JP2022034549A priority Critical patent/JP2022082565A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
JP2018538604A 2016-01-22 2017-01-23 がんを処置するための方法 Pending JP2019502741A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022034549A JP2022082565A (ja) 2016-01-22 2022-03-07 がんを処置するための方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662281962P 2016-01-22 2016-01-22
US62/281,962 2016-01-22
PCT/US2017/014578 WO2017127811A1 (en) 2016-01-22 2017-01-23 Methods for treating cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022034549A Division JP2022082565A (ja) 2016-01-22 2022-03-07 がんを処置するための方法

Publications (2)

Publication Number Publication Date
JP2019502741A true JP2019502741A (ja) 2019-01-31
JP2019502741A5 JP2019502741A5 (https=) 2020-12-24

Family

ID=59362109

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018538604A Pending JP2019502741A (ja) 2016-01-22 2017-01-23 がんを処置するための方法
JP2022034549A Abandoned JP2022082565A (ja) 2016-01-22 2022-03-07 がんを処置するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022034549A Abandoned JP2022082565A (ja) 2016-01-22 2022-03-07 がんを処置するための方法

Country Status (6)

Country Link
US (1) US20190030023A1 (https=)
EP (1) EP3405203A4 (https=)
JP (2) JP2019502741A (https=)
CN (1) CN108883132A (https=)
CA (1) CA3010617A1 (https=)
WO (1) WO2017127811A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109069426B (zh) 2015-12-14 2021-10-29 X4 制药有限公司 治疗癌症的方法
CA3008279A1 (en) 2015-12-14 2017-06-22 X4 Pharmaceuticals, Inc. Methods for treating cancer
WO2017112894A1 (en) 2015-12-22 2017-06-29 X4 Pharmaceuticals, Inc. Methods for treating immunodeficiency disease
CA3019394A1 (en) 2016-04-08 2017-10-12 X4 Pharmaceuticals, Inc. Methods for treating cancer
ES2870920T3 (es) 2016-06-21 2021-10-28 X4 Pharmaceuticals Inc Inhibidores de CXCR4 y usos de los mismos
EP3472129A4 (en) 2016-06-21 2019-12-04 X4 Pharmaceuticals, Inc. CXCR4 INHIBITORS AND USES THEREOF
CN109640988A (zh) 2016-06-21 2019-04-16 X4 制药有限公司 Cxcr4抑制剂及其用途
JP2020525427A (ja) * 2017-06-21 2020-08-27 エックス４ ファーマシューティカルズ， インコーポレイテッド 癌を処置するための方法
SG11202007590TA (en) 2018-02-13 2020-09-29 Merck Sharp & Dohme Methods for treating cancer with anti-pd-1 antibodies
WO2019200223A1 (en) * 2018-04-13 2019-10-17 X4 Pharmaceuticals, Inc. Cancer serum biomarkers and methods of use thereof
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
EP3878446A1 (en) * 2020-03-09 2021-09-15 Universite De Geneve Hsd11b1 inhibitors for use in immunotherapy and uses thereof
CA3171250A1 (en) 2020-03-10 2021-09-16 E. Lynne KELLEY Methods for treating neutropenia

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007332141A (ja) * 2006-06-12 2007-12-27 Pfizer Prod Inc 薬
WO2011147026A2 (en) * 2010-05-28 2011-12-01 Pharmascience, Inc. A stable pharmaceutical formulation comprising telmisartan and hydrochlorothiazide
US20150352208A1 (en) * 2013-08-05 2015-12-10 Cambridge Enterprise Limited Inhibition of cxcr4 signaling in cancer immunotherapy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070259040A1 (en) * 2006-05-01 2007-11-08 Cherukuri S R Novel triptan formulations and methods for making them
KR20150130284A (ko) * 2013-03-15 2015-11-23 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 암 백신 및 이를 이용한 치료 방법
IL292510A (en) * 2013-11-05 2022-06-01 Cognate Bioservices Inc Combinations of checkpoint inhibitors and therapeutics to treat cancer
MX382033B (es) * 2014-03-19 2025-03-13 Infinity Pharmaceuticals Inc Compuestos heterocíclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma.
RU2696312C2 (ru) * 2014-07-16 2019-08-01 Трансген Са Онколитический вирус для экспрессии модуляторов иммунологических контрольных точек
JP2018516969A (ja) * 2015-06-12 2018-06-28 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｐｄ−１およびｃｘｃｒ４シグナル伝達経路の組合せ遮断による癌の処置
CN109069426B (zh) * 2015-12-14 2021-10-29 X4 制药有限公司 治疗癌症的方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007332141A (ja) * 2006-06-12 2007-12-27 Pfizer Prod Inc 薬
WO2011147026A2 (en) * 2010-05-28 2011-12-01 Pharmascience, Inc. A stable pharmaceutical formulation comprising telmisartan and hydrochlorothiazide
US20150352208A1 (en) * 2013-08-05 2015-12-10 Cambridge Enterprise Limited Inhibition of cxcr4 signaling in cancer immunotherapy

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BRITISH JOURNAL OF CANCER, vol. 108, no. 8, JPN6021044343, 2013, pages 1634 - 1640, ISSN: 0004786094 *
CLINICAL CANCER RESEARCH, vol. 21, no. 13, JPN6021044342, 2015, pages 2892 - 2897, ISSN: 0004786095 *
ＴＨＥ ＮＥＷ ＥＮＧＬＡＮＤ ＪＯＵＲＮＡＬ ＯＦ ＭＥＤＩＣＩＮＥ, vol. 369, JPN6021007232, 2013, pages 134 - 144, ISSN: 0004786092 *
河上裕: "ヒト腫瘍免疫学とがん免疫療法のさらなる発展をめざして", 医学のあゆみ, vol. 252, no. 1, JPN6021007235, 2015, pages 105 - 110, ISSN: 0004786093 *

Also Published As

Publication number Publication date
CN108883132A (zh) 2018-11-23
US20190030023A1 (en) 2019-01-31
WO2017127811A1 (en) 2017-07-27
CA3010617A1 (en) 2017-07-27
JP2022082565A (ja) 2022-06-02
EP3405203A4 (en) 2019-07-24
EP3405203A1 (en) 2018-11-28

Similar Documents

Publication Publication Date Title
JP2022082565A (ja) がんを処置するための方法
US11337969B2 (en) Methods for treating cancer
US20230220063A1 (en) Il-1beta binding antibodies for use in treating cancer
CA3080821A1 (en) Cancer biomarkers and methods of use thereof
JP2019532051A (ja) Ｒａｆ阻害剤及びｅｒｋ阻害剤を含む治療用組合せ
CN112218658A (zh) 热量限制模拟物用于增强癌症治疗的化学免疫疗法的用途
KR20200014298A (ko) Her2 양성 암의 치료
JP2018537539A (ja) がんを処置する方法
TW201909920A (zh) 治療組合
KR20140040728A (ko) Pi3k 억제제 화합물을 사용한 중피종 치료 방법
ES3052701T3 (en) Sotorasib for use in the treatment of cancer
US20220184091A1 (en) Methods of Treating Cancer with Chk1 Inhibitors
WO2020128613A1 (en) Use of il-1beta binding antibodies
US20240165112A1 (en) Therapy for the treatment of cancer
JP2022532597A (ja) Ｃｈｋ１阻害剤を使用してがんを治療する方法
CN111712243A (zh) 治疗癌症的方法和组合疗法
CN121175048A (zh) 用法尼基转移酶抑制剂和pi3k抑制剂治疗鳞状细胞癌的方法
HK40028739A (en) Methods and combination therapy to treat cancer

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200123

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201113

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210304

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210604

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210804

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210901

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210901

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20211108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220307

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220307

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20220316

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220510

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220511

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20220603

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20220608